The anti-tumour effects of rapalogs, other mTOR inhibitors and elevated mTOR activity have been described previously in many tumours including gliomas, AMLs and chondrosarcomas (where the occurrence of the IDH mutation is remarkable) [46]. Here, IDH2 is linked to glioma.